Stoke Therapeutics (STOK) Operating Income (2018 - 2026)

Stoke Therapeutics' Operating Income history runs 9 years deep, the most recent figure standing at -$53.4 million for Q1 2026.

• In Q1 2026, Operating Income fell 148.02% year-over-year to -$53.4 million; the TTM figure through Mar 2026 stood at -$185.2 million (down 584.41% YoY), while the FY2025 annual figure was -$20.6 million, up 79.69% from the prior year.
• Operating Income was -$53.4 million for Q1 2026 at Stoke Therapeutics, up from -$61.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $111.2 million in Q1 2025 to a low of -$61.4 million in Q4 2025.
• Historically, Operating Income has averaged -$23.2 million across 5 years, with a median of -$27.3 million in 2025.
• Biggest YoY gain for Operating Income was 492.08% in 2025; the steepest drop was 350.0% in 2025.
• A 5-year view of Operating Income shows it stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then jumped by 53.85% to -$13.7 million in 2024, then plunged by 350.0% to -$61.4 million in 2025, then grew by 13.06% to -$53.4 million in 2026.
• The last three Operating Income figures came in at -$53.4 million (Q1 2026), -$61.4 million (Q4 2025), and -$43.1 million (Q3 2025), per Business Quant data.